Wedbush analyst Andreas Argyrides reiterated a Buy rating on Aerovate Therapeutics (AVTE – Research Report) today and set a price target of $54.00. The company’s shares closed yesterday at $19.29.
According to TipRanks, Argyrides is a 2-star analyst with an average return of 0.7% and a 35.29% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Immunic, and Ascendis Pharma.
Currently, the analyst consensus on Aerovate Therapeutics is a Moderate Buy with an average price target of $45.00.
See the top stocks recommended by analysts >>
AVTE market cap is currently $474.6M and has a P/E ratio of -10.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Read More on AVTE:
- Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
- Aerovate Therapeutics, Inc. (AVTE) Q4 Earnings Cheat Sheet
- Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
- Aerovate Therapeutics initiated with Buy, $36 target at Guggenheim
- Aerovate Therapeutics initiated with a Buy at Guggenheim
